1) Earnings of continuing business activities before taxes, depreciation and amortization 2)Based on group net profit and average shareholders' equity after deduction of the proposed dividend 3) Based on ordinary dividend of CHF 1.50 and share price on December 31, 2020
CEO interview
Milestones
Consistent strategy execution
Successful sale of Bank am Bellevue
Transformation to a pure specialized asset manager concluded
Evolution of time-tested business model and innovation across the product range continue
Strong operating performance
Record financial results despite turbulent markets
Convincing absolute and relative investment performance of Bellevue products
Attractive value created for shareholders and clients
Simplified and stronger platform
Simplified, robust and agile organization and capital base
Very resilient platform, primed for further growth
Solid governance with a focus on ESG
Financial highlights
Bellevue Group performed well as a pure play asset manager in an exceptional market environment in 2020. The detailed figures on the annual results can be found in the presentation.
Bellevue expands its product offering in the field of Private Equity
Bellevue Group AG is strengthening its private equity arm with the launch of the BB Entrepreneur Private strategy, an investment vehicle focused on growth financing for small and mid-sized Swiss companies. In addition to the successful venture capital fund BB Pureos Bioventures, Bellevue is now launching a new initiative to strengthen the Swiss SME landscape.
Venture Capital Fund raises USD 168 million and demand remains strong
BB Pureos Bioventures (Pureos) was launched two years ago as venture capital fund focused on private biotech companies developing novel medicines for severe diseases. Bellevue Asset Management AG, announced the closing of its first fund, BB Pureos Bioventures L.P. (“Pureos”) after receiving capital commitments of USD 168 mn. In view of the capital commitments received in early 2021 and the persisting high levels of interest, this fund will likely pass the USD 200 mn threshold at the end of March 2021, when the final closing is scheduled.
Interview with Dr. Daniel Koller, Head Investment Team BB Biotech
Dr. Daniel Koller is looking back on the challenging pandemic year 2020 in a video interview. First he discusses the groundbreaking success of the biotech industry. It has developed successful and safe vaccines in record time and is leading the fight against the SARS-CoV-2 virus pandemic with these vaccines and therapeutic antibodies. In addition, he explains why BB Biotech had already had invested in Moderna in 2018 and what opportunity he sees for the mRNA technology in the future. Finally he gives an insight into the portfolio and tells why he has added Biogen, in the portfolio.
